Mantle Cell Lymphoma

Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation, final results of a randomized trial showed.

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

The combination of lenalidomide and rituximab demonstrated an objective response rate of 92% as initial therapy for patients with mantle cell lymphoma.

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

The FDA has expanded the approval for bortezomib (Velcade) to include the frontline treatment of patients with mantle cell lymphoma.

The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia.

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).